{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:27:27Z","timestamp":1787498847203,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.mam.2026.101474","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:44:13Z","timestamp":1776357853000},"page":"101474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists across anti-inflammation"],"prefix":"10.1016","volume":"109","author":[{"given":"Daohong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mam.2026.101474_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.mam.2026.101474_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.14309\/ajg.0000000000003208","article-title":"Safety and effectiveness of Glucagon-like Peptide-1 receptor agonists in inflammatory bowel disease","volume":"120","author":"Anderson","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.mam.2026.101474_bib3","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mam.2026.101474_bib4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.mam.2026.101474_bib5","first-page":"59","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease","volume":"21","author":"Boumitri","year":"2025","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.mam.2026.101474_bib6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/metabo14100554","article-title":"Liraglutide therapy in obese patients alters macrophage phenotype and decreases their tumor necrosis factor alpha release and oxidative stress aarkers-a pilot study","volume":"14","author":"Bu\u0142dak","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.mam.2026.101474_bib7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/jcph.1100","article-title":"Dual targeting autoimmunity and cancer: from biology to medicine","volume":"58","author":"Chen","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.mam.2026.101474_bib8","first-page":"41","article-title":"Dually efficacious medicine against fibrosis and cancer","volume":"7","author":"Chen","year":"2019","journal-title":"Med. Sci."},{"key":"10.1016\/j.mam.2026.101474_bib9","first-page":"737","article-title":"Targeted therapy evolution: from defining a sub-population to crossing multi-indications","volume":"14","author":"Chen","year":"2024","journal-title":"Adv. Pharmaceut. Bull."},{"key":"10.1016\/j.mam.2026.101474_bib10","article-title":"Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mam.2026.101474_bib11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.mam.2026.101474_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.mam.2026.101474_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.mam.2026.101474_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175634","article-title":"The GLP-1 journey: from discovery science to therapeutic impact","volume":"134","author":"Drucker","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mam.2026.101474_bib15","article-title":"Biased agonism and polymorphic variation at the GLP-1 receptor: implications for the development of personalised therapeutics","volume":"184","author":"El","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mam.2026.101474_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovi\u0107","year":"2023","journal-title":"Front. Clin. Diabetes Healthc."},{"key":"10.1016\/j.mam.2026.101474_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/diseases12080186","article-title":"Therapeutic effects of semaglutide on nonalcoholic fatty liver disease with type 2 diabetes mellitus and obesity: an open-label controlled trial","volume":"12","author":"Gad","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.mam.2026.101474_bib18","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.mam.2026.101474_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.mam.2026.101474_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312852","article-title":"Association of gut microbiome and dipeptidyl peptidase 4 in immune-mediated inflammatory bowel disease: a rapid literature review","volume":"25","author":"Gomes","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2026.101474_bib21","article-title":"GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the Epi-IIRN","volume":"23","author":"Gorelik","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.mam.2026.101474_bib22","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.apsb.2024.03.011","article-title":"Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling","volume":"14","author":"He","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.mam.2026.101474_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109952","article-title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?","volume":"253","author":"H\u00f6lscher","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mam.2026.101474_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-Like Peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review","volume":"30","author":"Karacabeyli","year":"2024","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.mam.2026.101474_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13195-024-01573-x","article-title":"Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","volume":"16","author":"Koychev","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.mam.2026.101474_bib26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/ijms23020739","article-title":"GLP-1a: going beyond traditional use","volume":"23","author":"Laurindo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2026.101474_bib27","first-page":"62","article-title":"Breaking boundaries: chronic diseases and the frontiers of immune microenvironments","volume":"1","author":"Li","year":"2025","journal-title":"Media Res."},{"key":"10.1016\/j.mam.2026.101474_bib28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/ADR-230181","article-title":"Clinical evidence for GLP-1 receptor agonists in Alzheimer's disease: a systematic review","volume":"8","author":"Liang","year":"2024","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.mam.2026.101474_bib29","article-title":"Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: a nation-wide population-based cohort study","volume":"104","author":"Lin","year":"2025","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.mam.2026.101474_bib30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.mam.2026.101474_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mam.2026.101474_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.163","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): a systematic review","volume":"3","author":"Lv","year":"2020","journal-title":"Endocrinol. Diabetes Metab."},{"key":"10.1016\/j.mam.2026.101474_bib33","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.mam.2026.101474_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.462","article-title":"Glucagon-like peptide agonists: a prospective review","volume":"7","author":"Mariam","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"key":"10.1016\/j.mam.2026.101474_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1163288","article-title":"GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway","volume":"14","author":"Mazzieri","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mam.2026.101474_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mam.2026.101474_bib37","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2026.101474_bib38","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2968::AID-IMMU2968>3.0.CO;2-X","article-title":"Lineage-specific differences among CD8+ T cells in their dependence of NF-kappa B\/Rel signaling","volume":"29","author":"Mora","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.mam.2026.101474_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171200","article-title":"Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut","volume":"176","author":"Morrow","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.mam.2026.101474_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1342944","article-title":"The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype","volume":"18","author":"Noguchi","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.mam.2026.101474_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mam.2026.101474_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108176","article-title":"Macrophage immunometabolism in inflammatory bowel diseases: from pathogenesis to therapy","volume":"238","author":"Pan","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.mam.2026.101474_bib43","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.mam.2026.101474_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mam.2026.101474_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11883-018-0715-0","article-title":"The interplay of lipids, lipoproteins, and immunity in atherosclerosis","volume":"20","author":"Pirillo","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.mam.2026.101474_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mam.2026.101474_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.mam.2026.101474_bib48","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mam.2026.101474_bib49","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mam.2026.101474_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.mam.2026.101474_bib51","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41401-020-0490-7","article-title":"Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation","volume":"42","author":"Song","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.mam.2026.101474_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3892\/etm.2023.11948","article-title":"Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: a double-blind, randomized controlled clinical trial","volume":"25","author":"Sun","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.mam.2026.101474_bib53","doi-asserted-by":"crossref","unstructured":"Villumsen M, Schelde AB, Jimenez-Solem E, et al. GLP-1 based therapies and disease course of inflammatory bowel disease. eClinicalMedicine 202;37:100979.","DOI":"10.1016\/j.eclinm.2021.100979"},{"key":"10.1016\/j.mam.2026.101474_bib54","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.mam.2026.101474_bib55","first-page":"47","article-title":"Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective","volume":"13","author":"Wang","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.mam.2026.101474_bib56","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.18632\/aging.204953","article-title":"The alleviating effect and mechanism of GLP-1 on ulcerative colitis","volume":"15","author":"Wang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.mam.2026.101474_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241271886","article-title":"Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy","volume":"16","author":"Williams","year":"2024","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.mam.2026.101474_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113499","article-title":"Tirzepatide's role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance","volume":"143","author":"Xia","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.mam.2026.101474_bib59","article-title":"Anti-inflammatory benefits of semaglutide: state of the art","volume":"36","author":"Yaribeygi","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.mam.2026.101474_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mam.2026.101474_bib61","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2025.03.003","article-title":"Structural pharmacology and mechanisms of GLP-1R signaling","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.mam.2026.101474_bib62","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai osteoarthritis cohort","volume":"82","author":"Zhu","year":"2023","journal-title":"Ann. Rheum. Dis."}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299726000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299726000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:32:03Z","timestamp":1781915523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299726000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":62,"alternative-id":["S0098299726000300"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2026.101474","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists across anti-inflammation","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2026.101474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101474"}}